Home » QIDP » Page 7

Tag Archives: QIDP

What’s in a Name?  Would ‘Carbavance’ Still Smell as Sweet?

Posted on by — No Comments ↓

Since the publication of a series of posters at ICAAC 2014, we finally know what’s hidden behind the ‘Carbavance’ name.  ‘Carbavance’ stands for the combination of meropenem with the B-lactamase inhibitor RPX7009 which The Medicines Company (TMC) inlicensed from Rempex Pharmaceuticals a few years ago.  This is the ‘Carbavance’ which Continue reading What’s in a Name?  Would ‘Carbavance’ Still Smell as Sweet?→

Some Thoughts about Eravacycline Based on the Phase 2 cIAI Study

Posted on by — No Comments ↓

Solomkin et al. conclude that the efficacy and safety of eravacycline compares favorably to the control drug, ertapenem.[1]  This top-level assessment is made with the usual caveats (insufficient statistical power, small sample size), but a few points deserve comment. Eravacycline is a fluorocycline; as a tetracycline derivative it follows into Continue reading Some Thoughts about Eravacycline Based on the Phase 2 cIAI Study→

BC-3781 Passes Phase 2 with Flying Colors, Readies for Phase 3

Posted on by — No Comments ↓

The pleuromutilins are a relatively ‘old’ class of antibiotics that have seen much use in veterinary but not in human medicine.  According to EMA, Tiamulin is an “essential antibiotic” for the control of dysentery in pigs which is caused by Brachyspira hyodysenteriae, a macrolide-resistant pathogen.[1]  Retapamulin / Altabax® was introduced Continue reading BC-3781 Passes Phase 2 with Flying Colors, Readies for Phase 3→